Mainz Biomed NV
MYNZ
Company Profile
Business description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Contact
Robert Koch Strasse 50
Sirius Gutenberg Park
MainzRP55129
DEUT: +49 61315542860
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
26
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,280.04 | 33.08 | -0.40% |
| DAX 40 | 25,297.76 | 54.63 | -0.22% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,237.15 | 1.79 | -0.02% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |